The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes
Open Access
- 4 March 2014
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 43
Abstract
Circulating endocannabinoid levels are increased in obesity and diabetes. We have shown that fatty acid amide hydrolase (FAAH, an endocannabinoid hydrolysing enzyme) in subcutaneous adipose tissue positively correlates with BMI in healthy volunteers. The aim of the present study was to investigate whether the hydrolytic enzymes of the endocannabinoid system are affected by diabetes or metabolic syndrome in obesity. Using radiolabelled substrates, FAAH and monoacylglycerol lipase (MGL) activities were assessed in adipocytes from various adipose depots in Zucker rats (n = 22, subcutaneous abdominal, visceral and epididymal) and bariatric patients (n = 28, subcutaneous abdominal and omental). FAAH activity was significantly increased in adipocytes of obese (Zucker Fatty) compared to Zucker lean rats (P < 0.05) but was not raised in the Zucker Diabetic Fatty rats (ZDF). MGL activity was raised in both Zucker Fatty (P < 0.001-0.01) and ZDF rats (P < 0.05) and was positively correlated with body weight and plasma glucose levels (P < 0.01). In bariatric patients (BMI range 37–58 kg.m2), there was a trend for MGL activity to correlate positively with BMI, reaching significance when type 2 diabetic patients were removed. FAAH and MGL activities in obese humans were not correlated with blood pressure, skinfold thicknesses, fasting glucose, insulin, HbA1c, triglycerides or cholesterol levels. FAAH in adipocytes is differentially altered in animal models of obesity and diabetes, while MGL activity is increased by both. However, in obese humans, FAAH or MGL activity in adipocytes is not affected by diabetes, dyslipidaemia or other markers of metabolic dysfunction. This suggests increased circulating levels of endocannabinoids are not a result of altered degradation in adipose tissue.Keywords
This publication has 31 references indexed in Scilit:
- Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and EndocannabinoidsPLOS ONE, 2012
- Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exerciseLipids in Health and Disease, 2011
- The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humansLipids in Health and Disease, 2011
- Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patientsLipids in Health and Disease, 2010
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Receptors for acylethanolamides—GPR55 and GPR119Prostaglandins & Other Lipid Mediators, 2009
- GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-CellDiabetes, 2009
- Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese menInternational Journal of Obesity, 2007
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992